Challenges in metabolomics for a given spectrum of disease are more or less comparable,
ranging from the accurate measurement of metabolite abundance, compound annotation …

Prostate cancer (PCA) is the second most common tumour in men worldwide. Whereas
prostate specific antigen (PSA) is an established biochemical marker, the optimal imaging …

Purpose To prospectively evaluate the potential value of fluorocholine (FCH) positron
emission tomography (PET)/computed tomography (CT) in the preoperative staging of …

Purpose The aim of this prospective study was to compare the potential value of 18 F
fluorocholine (FCH) and 18 F fluoride positron emission tomography (PET)–CT scanning for …

The high mortality and financial burden associated with prostate cancer can be partly
attributed to a lack of sensitive screening methods for detection and staging of the disease …

Background Positron emission tomography/computed tomography (PET/CT) has recently
emerged as a promising diagnostic imaging platform for prostate cancer. Several …

In prostate cancer, bone is the second most common site of metastatic disease after lymph
nodes. This is related to a poor prognosis and is one of the major causes of morbidity and …

The presence of positron emission tomography (PET) centers at most major hospitals
worldwide, along with the improvement of PET scanner sensitivity and the introduction of …

The current diagnosis and management of prostate cancer is largely based on the use of
serum prostate-specific antigen (PSA) and pathologic risk factors such as Gleason score …

Noninvasive imaging techniques have been used in the past for visualization the functional
activity of the bone marrow compartment. Imaging with radiolabelled compounds may allow …